Pliant Therapeutics (PLRX) Stock Forecast & Price Target

Compare

509 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PLRX Analyst Ratings

Hold

1 Buy

6 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Pliant

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PLRX Stock 12 Month Forecast

Average Price Target

$6.50

▲(306.25%Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Pliant Therapeutics in the last 3 months. The average price target is $6.50 with a high forecast of $17.00 and a low forecast of $2.00. The average price target represents a 306.25% change from the last price of $1.60.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","19":"$19","4.75":"$4.75","9.5":"$9.5","14.25":"$14.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.75,9.5,14.25,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Aug<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.62,2.8030769230769232,3.986153846153846,5.169230769230769,6.352307692307692,7.535384615384615,8.718461538461536,9.901538461538461,11.084615384615383,12.267692307692307,13.450769230769229,14.633846153846154,15.816923076923075,{"y":17,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.62,1.9953846153846155,2.370769230769231,2.746153846153846,3.121538461538462,3.496923076923077,3.8723076923076922,4.247692307692308,4.623076923076923,4.998461538461538,5.373846153846154,5.74923076923077,6.124615384615384,{"y":6.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.62,1.6492307692307693,1.6784615384615384,1.7076923076923078,1.736923076923077,1.7661538461538462,1.7953846153846154,1.8246153846153847,1.853846153846154,1.883076923076923,1.9123076923076923,1.9415384615384617,1.9707692307692308,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.42,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.54,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.81,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.66,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.13,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.86,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.35,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.29,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.52,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.75,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$17.00

Average Price Target$6.50

Lowest Price Target$2.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Edward NashCanaccord Genuity

Canaccord Genuity

Hold

150.00%

Upside

Reiterated

05/11/25

Cautious Hold Rating on Pliant Therapeutics Amid Clinical and Financial Uncertainties

Joseph StringerNeedham

Needham

―

Hold

―

Reiterated

05/09/25

Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (NASDAQ: TRVI), Pliant Therapeutics (NASDAQ: PLRX) and Qiagen (NYSE: QGEN)

Yasmeen RahimiPiper Sandler

Piper Sandler

$17

Buy

962.50%

Upside

Reiterated

05/09/25

Piper Sandler Keeps Their Buy Rating on Pliant Therapeutics (PLRX)

Jeff JonesOppenheimer

Oppenheimer

―

Hold

―

Reiterated

05/09/25

Oppenheimer Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)

Faisal KhurshidLeerink Partners

Leerink Partners

Hold

25.00%

Upside

Reiterated

05/08/25

Cautious Hold Rating for Pliant Therapeutics Amidst Strategic Restructuring and Drug Development Uncertainties

Brian AbrahamsRBC Capital

RBC Capital

Hold

87.50%

Upside

Reiterated

05/08/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Knight Therapeutics (Other OTC: KHTRF), Pliant Therapeutics (NASDAQ: PLRX) and Pacira Pharmaceuticals (NASDAQ: PCRX)

Ed ArceH.C. Wainwright

H.C. Wainwright

―

Hold

―

Reiterated

03/18/25

Neutral Rating on Pliant Therapeutics Amid Early Promising Data and Uncertainties

Tiago FauthWells Fargo

Wells Fargo

$4→$3

Hold

87.50%

Upside

Reiterated

03/04/25

Wells Fargo Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)

David LebowitzCiti

Citi

$4→$1.5

Hold

-6.25%

Downside

Reiterated

03/03/25

Cautious Hold Rating on Pliant Therapeutics Amid Uncertainty Over Bexotegrast Trial and Financial OutlookWe offset this reduction by an assumption of substantially lower operating spend. Our new target price is $1.50 (from $4).

Pete StavropoulosCantor Fitzgerald

Cantor Fitzgerald

―

Hold

―

Initiated

03/03/25

Hold Rating on Pliant Therapeutics Amidst BEACON-IPF Study Discontinuation and Uncertainty in Pipeline Prioritization

Alex Thompson CFAStifel Nicolaus

Stifel Nicolaus

$32→$3

Hold

87.50%

Upside

Downgraded

03/03/25

Pliant Therapeutics downgraded to Hold from Buy at StifelPliant Therapeutics downgraded to Hold from Buy at Stifel

Ritu BaralTD Cowen

TD Cowen

―

Buy

―

Reiterated

02/18/25

TD Cowen Keeps Their Buy Rating on Pliant Therapeutics (PLRX)

Eric JosephJ.P. Morgan

J.P. Morgan

―

Hold

―

Downgraded

02/10/25

Pliant Therapeutics downgraded to Neutral from Overweight at JPMorganPliant Therapeutics downgraded to Neutral from Overweight at JPMorgan

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Edward NashCanaccord Genuity

Canaccord Genuity

Hold

150.00%

Upside

Reiterated

05/11/25

Cautious Hold Rating on Pliant Therapeutics Amid Clinical and Financial Uncertainties

Joseph StringerNeedham

Needham

―

Hold

―

Reiterated

05/09/25

Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (NASDAQ: TRVI), Pliant Therapeutics (NASDAQ: PLRX) and Qiagen (NYSE: QGEN)

Yasmeen RahimiPiper Sandler

Piper Sandler

$17

Buy

962.50%

Upside

Reiterated

05/09/25

Piper Sandler Keeps Their Buy Rating on Pliant Therapeutics (PLRX)

Jeff JonesOppenheimer

Oppenheimer

―

Hold

―

Reiterated

05/09/25

Oppenheimer Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)

Faisal KhurshidLeerink Partners

Leerink Partners

Hold

25.00%

Upside

Reiterated

05/08/25

Cautious Hold Rating for Pliant Therapeutics Amidst Strategic Restructuring and Drug Development Uncertainties

Brian AbrahamsRBC Capital

RBC Capital

Hold

87.50%

Upside

Reiterated

05/08/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Knight Therapeutics (Other OTC: KHTRF), Pliant Therapeutics (NASDAQ: PLRX) and Pacira Pharmaceuticals (NASDAQ: PCRX)

Ed ArceH.C. Wainwright

H.C. Wainwright

―

Hold

―

Reiterated

03/18/25

Neutral Rating on Pliant Therapeutics Amid Early Promising Data and Uncertainties

Tiago FauthWells Fargo

Wells Fargo

$4→$3

Hold

87.50%

Upside

Reiterated

03/04/25

Wells Fargo Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)

David LebowitzCiti

Citi

$4→$1.5

Hold

-6.25%

Downside

Reiterated

03/03/25

Pete StavropoulosCantor Fitzgerald

Cantor Fitzgerald

―

Hold

―

Initiated

03/03/25

Hold Rating on Pliant Therapeutics Amidst BEACON-IPF Study Discontinuation and Uncertainty in Pipeline Prioritization

Alex Thompson CFAStifel Nicolaus

Stifel Nicolaus

$32→$3

Hold

87.50%

Upside

Downgraded

03/03/25

Pliant Therapeutics downgraded to Hold from Buy at StifelPliant Therapeutics downgraded to Hold from Buy at Stifel

Ritu BaralTD Cowen

TD Cowen

―

Buy

―

Reiterated

02/18/25

TD Cowen Keeps Their Buy Rating on Pliant Therapeutics (PLRX)

Eric JosephJ.P. Morgan

J.P. Morgan

―

Hold

―

Downgraded

02/10/25

Pliant Therapeutics downgraded to Neutral from Overweight at JPMorganPliant Therapeutics downgraded to Neutral from Overweight at JPMorgan

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pliant Therapeutics

1 Month

xxx

Success Rate

8/16 ratings generated profit

Average Return

-4.60%

reiterated a xxx

rating 28 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -4.60% per trade.

3 Months

xxx

Success Rate

8/16 ratings generated profit

Average Return

+12.64%

reiterated a xxx

rating 28 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +12.64% per trade.

1 Year

Yasmeen RahimiPiper Sandler

Success Rate

4/16 ratings generated profit

Average Return

-18.93%

reiterated a buy rating 28 days ago

Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -18.93% per trade.

2 Years

xxx

Success Rate

3/16 ratings generated profit

Average Return

-50.01%

reiterated a xxx

rating 28 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 18.75% of your transactions generating a profit, with an average return of -50.01% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PLRX Analyst Recommendation Trends

Rating

Nov 24

Jan 25

Feb 25

Mar 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PLRX has received 12 Buy Ratings, 24 Hold Ratings, and 0 Sell Ratings. PLRX average Analyst price target in the past 3 months is 6.50.

Each month's total comprises the sum of three months' worth of ratings.

PLRX Financial Forecast

PLRX Earnings Forecast

Next quarter’s earnings estimate for PLRX is -$0.65 with a range of -$1.09 to -$0.36. The previous quarter’s EPS was -$0.92. PLRX beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year PLRX has Outperformed its overall industry.

PLRX Sales Forecast

Next quarter’s sales forecast for PLRX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. PLRX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year PLRX has Preformed in-line its overall industry.

PLRX Stock Forecast FAQ

What is PLRX’s average 12-month price target, according to analysts?

Based on analyst ratings, Pliant Therapeutics’s 12-month average price target is 6.50.

What is PLRX’s upside potential, based on the analysts’ average price target?

Pliant Therapeutics has 306.25% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PLRX a Buy, Sell or Hold?

Pliant Therapeutics has a consensus rating of Hold which is based on 1 buy ratings, 6 hold ratings and 0 sell ratings.

What is Pliant Therapeutics’s price target?

The average price target for Pliant Therapeutics is 6.50. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $17.00 ,the lowest forecast is $2.00. The average price target represents 306.25% Increase from the current price of $1.6.

What do analysts say about Pliant Therapeutics?

Pliant Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of PLRX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Pliant Therapeutics (PLRX) Stock Forecast & Price Target

PLRX Analyst Ratings

PLRX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Pliant Therapeutics

PLRX Analyst Recommendation Trends

PLRX Financial Forecast

PLRX Earnings Forecast

PLRX Sales Forecast

PLRX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts